Navigation Links
Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease
Date:2/16/2009

LOS ANGELES, Feb. 16 /PRNewswire/ -- Scientists announced today the publication of a landmark peer-reviewed paper in the February issue of the Bentham Open Stem Cell Journal which outlines the long term results of the world's first clinical trial using autologous neural stem cells for the treatment of Parkinson's disease. According to lead author, Michel F. Levesque, MD, FRCS(C), FACS, "We have documented the first successful adult neural stem cell transplantation to reverse the effects of Parkinson's disease and demonstrated the long term safety and therapeutic effects of this approach." Dr Levesque is a principal investigator for NeuroGeneration, a biotechnology company, and is affiliated with the UCLA School of Medicine and the Brain Research Institute.

The researcher reports that the publication of the article, "Therapeutic Microinjection of Autologous Adult Human Neural Stem Cells and Differentiated Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome" in the Bentham Open Stem Cell Journal heralds an important moment in regenerative and personalized medicine. "Our paper describes how we were able to isolate patient-derived neural stem cells, multiply them in vitro and ultimately differentiate them to produce mature neurons before they are reintroduced into the brain's basal ganglia. This is performed without the patient requiring immunosuppressants. Of particular note are the striking results this study yielded -- for the five years following the procedure the patient's motor scales improved by over 80% for at least 36 months. A word of caution must be added however, since this is a single case study, a larger clinical trial is needed to replicate these findings," says Levesque.

"We have been pioneering the use of neural stem cells for neurodegenerative disorders since 1998 and were the first research team to successfully use differentiated adult neural stem cells for the cellular restoration and treatment of Parkinson's disease. Our original methodology is based on the replication of several steps in human neurogenesis to regenerate millions of mature neurons characterized before transplantation. These steps are essential to establish safety, efficacy and to understand mechanisms of brain repair. The autologous approach mitigates the long term risks associated with allogenic transplants, including infection, inflammatory response, immune rejection, and poor biologic efficacy. In addition, we believe it was the combination of dopaminergic and GABA-ergic neurons that produced the long- lasting motor improvement. This suggests that in humans, Parkinson's disease is more than a chronic dopaminergic dysfunction and involves the GABA-ergic system with its glial environment. The relevance of this discovery cannot be understated because it questions the classical dopaminergic model of Parkinson's disease," says Levesque.

Scientists at NeuroGeneration are planning a larger prospective clinical trial for Parkinson's disease. "It's our hope that this trial will result in the launch of a cost-effective and lasting therapies for the millions of patients suffering from debilitating neurodegenerative disorders," concludes Levesque.

ABOUT NEUROGENERATION:

NeuroGeneration, a biotechnology company, is engaged in the development of biological products for the repair of neurological disorders. The company has completed a Phase I clinical trial for Parkinson's disease using adult derived neural stem cells. It intends to start a Phase II study for the treatment of Parkinson's disease as soon as it received final approval from the FDA. It is also planning Phase I studies for multiple systems atrophy, atypical parkinsonism, stroke, spinal cord and brain injuries, and Alzheimer's disease. The company was founded in 1998 and is headquartered in Los Angeles, California.

     FOR MORE INFORMATION CONTACT:
     Heather Larrabee
     NeuroGeneration
     310.659.3880
     heather@neurogeneration.com
    http://www.neurogeneration.com

'/>"/>
SOURCE NeuroGeneration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
6. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
7. Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting
8. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
11. AAOMS Updates BRONJ Position Paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
Breaking Medicine Technology:
(Date:5/19/2017)... ... 18, 2017 , ... ML Billing, 2016 Billing Company of the Year ... in large group practices, is pleased to announce their 30th anniversary. Not only has ... standard in all aspects of full-service medical billing. This has allowed ML Billing to ...
(Date:5/19/2017)... ... May 18, 2017 , ... ... who served eight American presidents of both political parties, will become the 9th ... General Colin L. Powell, USA (Retired) as Chairman in May, 2018. , Secretary ...
(Date:5/18/2017)... MD (PRWEB) , ... May 18, 2017 , ... Dr. ... disease treatment and educating her community on the link between this condition and serious ... have moderate to severe periodontal disease in Annapolis, MD, and seeking treatment ...
(Date:5/18/2017)... ... May 18, 2017 , ... Summit BHC (Summit), ... acquisition of English Mountain Recovery. Located in Sevierville, Tennessee approximately 30 miles ... in the state and brings the Company’s total number of operating facilities to ...
(Date:5/18/2017)... Boulder, CO (PRWEB) , ... May 18, 2017 , ... ... spotlight on low-performing schools. A remedy offered to “turn around” low-performance in school districts ... elsewhere. , School Closure as a Strategy to Remedy Low Performance , authored ...
Breaking Medicine News(10 mins):